4M Therapeutics Inc.
Early-stage biotechnology company developing targeted therapies for central nervous system disorders. Uses human induced pluripotent stem cell-derived neuronal models to discover and optimize small molecules and peptide therapeutics that modulate pathways related to neuroplasticity, neurogenesis, and neuroinflammation. Pipeline activity includes selective kinase inhibitors and peptide inhibitors with supporting preclinical pharmacology, GLP toxicology, and planning for first-in-human studies.
Industries
Nr. of Employees
small (1-50)
Products
4MT2001 (lead GSK3β inhibitor)
Selective small-molecule GSK3β inhibitor developed as a lead clinical candidate; demonstrated CNS target engagement and tolerability in preclinical studies.
4MT-01 series (GSK3β inhibitor series)
Series of potent and selective small-molecule GSK3β inhibitors in development for indications such as agitation in Alzheimer’s disease.
4MT-04 series (CDK5/p25 peptide inhibitor)
Peptide inhibitor series targeting the hyperactivated CDK5/p25 complex with preclinical activity in models of tau pathology and neurodegeneration.
4MT-A
A novel small molecule GSK3β inhibitor demonstrating potent effects for the treatment of bipolar disorder with CNS target engagement and efficacy comparable to lithium at significantly lower doses.
4MT-B
A novel small molecule GSK3β inhibitor demonstrating potent effects for the treatment of bipolar disorder with CNS target engagement and efficacy comparable to lithium at significantly lower doses.
4MT2001
4MT2001 is the primary metabolite of ruboxistaurin, combining de-risked clinical safety with improved GSK3β potency and selectivity, superior pharmacokinetic and pharmacodynamic profile, and potential for once daily dosing. It is being developed as a best-in-class treatment for bipolar disorder.
4MT2001 (lead GSK3β inhibitor)
Selective small-molecule GSK3β inhibitor developed as a lead clinical candidate; demonstrated CNS target engagement and tolerability in preclinical studies.
4MT-01 series (GSK3β inhibitor series)
Series of potent and selective small-molecule GSK3β inhibitors in development for indications such as agitation in Alzheimer’s disease.
4MT-04 series (CDK5/p25 peptide inhibitor)
Peptide inhibitor series targeting the hyperactivated CDK5/p25 complex with preclinical activity in models of tau pathology and neurodegeneration.
4MT-A
A novel small molecule GSK3β inhibitor demonstrating potent effects for the treatment of bipolar disorder with CNS target engagement and efficacy comparable to lithium at significantly lower doses.
4MT-B
A novel small molecule GSK3β inhibitor demonstrating potent effects for the treatment of bipolar disorder with CNS target engagement and efficacy comparable to lithium at significantly lower doses.
4MT2001
4MT2001 is the primary metabolite of ruboxistaurin, combining de-risked clinical safety with improved GSK3β potency and selectivity, superior pharmacokinetic and pharmacodynamic profile, and potential for once daily dosing. It is being developed as a best-in-class treatment for bipolar disorder.
Expertise Areas
- iPSC-based drug discovery
- CNS drug discovery and translational neuroscience
- Preclinical pharmacology and toxicology
- Biomarker discovery and translational validation
Key Technologies
- Induced pluripotent stem cell-derived neuronal cultures
- High-content kinetic imaging
- Phenotypic screening
- Small-molecule kinase inhibition (GSK3β)
News & Updates
Company CEO presented on biomarker development strategies and translational approaches at the 9th Annual Biomarker and Companion Diagnostics Conference.
Webinar presenting pipeline progress, platform capabilities, and plans toward clinical trial initiation, including fundraising and program updates.
Agreement to provide novel compounds for a National Institute on Aging-funded research project studying age-equivalent neurons from MCI patients; project awarded $3.9M.
Received a $120,000 grant from the SynGAP Research Fund to evaluate GSK3β inhibitors in preclinical SYNGAP1-related disorder studies.
Completed GLP repeat-dose toxicology studies in rodent and non-rodent species showing tolerability at high exposures and no adverse cardiovascular effects; supports Phase 1 readiness.
Signed an exclusive patent license agreement to advance a pipeline compound toward clinical development.
Company CEO presented on biomarker development strategies and translational approaches at the 9th Annual Biomarker and Companion Diagnostics Conference.
Webinar presenting pipeline progress, platform capabilities, and plans toward clinical trial initiation, including fundraising and program updates.
Agreement to provide novel compounds for a National Institute on Aging-funded research project studying age-equivalent neurons from MCI patients; project awarded $3.9M.
Received a $120,000 grant from the SynGAP Research Fund to evaluate GSK3β inhibitors in preclinical SYNGAP1-related disorder studies.
Completed GLP repeat-dose toxicology studies in rodent and non-rodent species showing tolerability at high exposures and no adverse cardiovascular effects; supports Phase 1 readiness.
Signed an exclusive patent license agreement to advance a pipeline compound toward clinical development.